Relmada Therapeutics, Inc. announced the completion of patient treatment in RELIANCE III, a monotherapy registrational Phase 3 trial evaluating REL-1017, the Company's novel NMDA receptor (NMDAR) channel blocker, for major depressive disorder (MDD). Relmada expects to report top-line data from the RELIANCE III trial early next quarter. The FDA has recently granted Fast Track Designation for REL-1017 as a monotherapy for the treatment of major depressive disorder.

Relmada's late-stage development program for REL-1017 includes RELIANCE III, the Phase 3 two-arm, placebo-controlled registrational study for REL-1017 as a potential monotherapy treatment of MDD, as well as RELIANCE I and RELIANCE II, two ongoing Phase 3, two-arm, placebo-controlled, pivotal studies evaluating REL-1017 as a potential adjunctive treatment for MDD. The RELIANCE development program also includes Reliance-OLS, a long-term open-label safety study that is enrolling rollover participants from all three pivotal studies, as well as de novo participants.